ESR1 and triple-negative breast carcinoma: In subgroup analysis, the HR of DFS was 0.45 (95% CI 0.34–0.59) for ER positive patients, 0.42 (95% CI 0.26–0.67) for ER negative patients, and 0.40 (95% CI 0.23–0.69) for patients with triple negative breast cancer (TNBC) (Figure 3).